Omnitrope’s Low Switch Rate Due To Inferior Delivery Device - Express Scripts
Executive Summary
A delivery device of Sandoz's follow-on recombinant human growth hormone Omnitrope that "doesn't cut it" has led to a low generic substitution rate that will not predict the substitutability of future generic biologics, Express Scripts Chief Medical Officer Steven Miller said at a Food and Drug Law Institute conference Nov. 15
You may also be interested in...
Biosimilar Pricing: Sandoz Vows Not To Make Omnitrope ‘Mistake’ With Filgrastim
Sandoz, Hospira execs say U.S. payers and consumers will ‘not be disappointed’ in cost savings from products approved under the 351(k) pathway, but warn that price alone may not tell whole story.
Civitas’ Inhaled L-Dopa Candidate To Start Phase 1, Backed by Michael J. Fox Foundation Grant
Parkinson’s disease is crowded, but Civitas’ value proposition is attractive because the unmet need remains high, the technology shows promise, the clinical trials are straightforward and relatively rapid, and the company, a spinout of Alkermes, starts with clinically validated assets and infrastructure.
Price Isn't Enough: Sandoz Hones Biosimilars Strategy With Lessons From Omnitrope
As FDA fleshes out the beginnings of a biosimilar regulatory pathway in the U.S., Novartis AG's generics business Sandoz is starting to draw important lessons in how to effectively commercialize copy-cat biologics.